The meeting is organized in even-numbered years since 1948. As per its tradition, the symposium aims to bring together medicinal chemists working in the pharmaceutical industry, academia, government, and private research institutions. The 2022 Edition will be Co-Chaired by Amjad Ali, Merck & Co. Inc. and Robert DeVita, Icahn School of Medicine at Mt Sinai.
The Scientific Organizing Committee has arranged a distinguished lineup of speakers. The program of this high-profile and international scientific meeting will be composed of six Sessions presenting hot topics and emerging trends in medicinal chemistry and drug discovery.
The Program will include the following Sessions:
Integrating Novel Chemical Modalities in Hit-to-lead: a New Paradigm for Early Drug Discovery
Chair: Maria-Jesus Blanco (Atavistik Bio)
New Directions in Targeting DNA Damage Repair (DDR)
Chairs: Erin DiMauro (Merck & Co. Inc.) and Srinivasa Karra (Avilar Therapeutics)
Hot Targets from NYC Academic and Biotech Scene
Chairs: Robert DeVita (Icahn School of Medicine at Mt Sinai) and Amjad Ali (Merck & Co. Inc.)
Targeting Autophagy for Cancer, Neurodegeneration, or Autoimmune Disease
Chairs: Erin DiMauro (Merck & Co. Inc.) and Hongjun Zhang (Cerevel Therapeutics, LLC.)
Next Generation Therapies Shaped by Clinical Data
Chair: Matthew Volgraf (Genentech Inc.)
Lessons from Drug Hunters across Academia, NPOs and the Pharmaceutical Industry
Chair: Phil Kym (AbbVie)